

In Press

1. Chakrabarty, A., Mackie, S., Harden, C. and **Morgan, A.W.** 010 Temporal artery biopsy: audit, scoring and reporting. *Rheumatology*. 2019, **58**.

Publications

* Both authors contributed equally to this work

(1-137)

2019

1. Wu, J., Keeley, A., Mallen, C., **Morgan, A.W.** and Pujades-Rodriguez, M. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. *CMAJ*. 2019, **191**, pp.E680-E688.
2. Spiliopoulou, A., Colombo, M., Plant, D., Nair, N., Cui, J., Coenen, M.J., Ikari, K., Yamanaka, H., Saevarsdottir, S., Padyukov, L., Bridges Jr., S.L., Kimberly, R.P., Okada, Y., van Riel, P.L.C., Wolbink, G., van der Horst-Bruinsma, I.E., de Vries, N., Tak, P.P., Ohmura, K., Canhão, H., Guchelaar, H.-J., Huizinga, T.W., Criswell, L.A., Raychaudhuri, S., Weinblatt, M.E., Wilson, A.G., Mariette, X., Isaacs, J.D., **Morgan, A.W.**, Pitzalis, C., Barton, A. and McKeigue, P. Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. *Ann Rheum Dis*. 2019, **78**, pp.1055-1061.
3. Mortimer, I., Bissell, L.-A., Hensor, E.M.A., Kozera, L., Mackie, S.L., Burska, A.N., Nam, J.L., Keen, H., Villeneuve, E., Donica, H., Buch, M.H., Conaghan, P.G., Emery, P., **Morgan, A.W.** and Andrews, J. Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. *Rheumatology*. 2019.
4. Mebrahtu, T.F., **Morgan, A.W.**, Keeley, A., Baxter, P.D., Stewart, P.M. and Pujades-Rodriguez, M. Dose Dependency of Iatrogenic Glucocorticoid Excess and Adrenal Insufficiency and Mortality: A Cohort Study in England. *J Clin Endocr Metab*. 2019, **104**, pp.3757-3767.
5. Hensor, E.M.A., McKeigue, P., Ling, S.F., Colombo, M., Barrett, J.H., Nam, J.L., Freeston, J., Buch, M.H., Spiliopoulou, A., Agakov, F., Kelly, S., Lewis, M.J., Verstappen, S.M.M., MacGregor, A.J., Viatte, S., Barton, A., Pitzalis, C., Emery, P., Conaghan, P.G. and **Morgan, A.W.** Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. *Rheumatology*. 2019, **58**, pp.1400-1409.

2018

6. Twigg, S., Hensor, E.M.A., Freeston, J., Tan, A.L., Emery, P., Tennant, A., **Morgan, A.W.**, YEAR, t. and Consortia, I. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era. *Arthritis Care Res*. 2018, **70**, pp.361-368.
7. Taylor, J.C., Bongartz, T., Massey, J., Mifsud, B., Spiliopoulou, A., Scott, I.C., Wang, J., Morgan, M., Plant, D., Colombo, M., Orchard, P., Twigg, S., McInnes, I.B., Porter, D., Freeston, J.E., Nam, J.L., Cordell, H.J., Isaacs, J.D., Strathdee, J.L., Arnett, D., de Hair,

- M.J.H., Tak, P.P., Aslibekyan, S., van Vollenhoven, R.F., Padyukov, L., Bridges, S.L., Pitzalis, C., Cope, A.P., Verstappen, S.M.M., Emery, P., Barnes, M.R., Agakov, F., McKeigue, P., Mushiroda, T., Kubo, M., Weinshilboum, R., Barton, A., **Morgan, A.W.**, Barrett, J.H., on behalf of the, M., and, P. and Consortia. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. *Pharmacogenomics J.* 2018, **18**, pp.528-538.
8. Robinson, J.I., Baxter, E.W.* , Owen, R.L.* , Thomsen, M.* , Tomlinson, D.C.* , Waterhouse, M.P., Win, S.J., Nettleship, J.E., Tiede, C., Foster, R.J., Owens, R.J., Fishwick, C.W.G., Harris, S.A., Goldman, A., McPherson, M.J. and **Morgan, A.W.** Affimer proteins inhibit immune complex binding to FcγR11a with high specificity through competitive and allosteric modes of action. *Proc Natl Acad Sci U S A.* 2018, **115**, pp.E72-E81.
 9. Ortiz-Fernández, L., Carmona, F.D., López-Mejías, R., González-Escribano, M.F., Lyons, P.A., **Morgan, A.W.**, Sawalha, A.H., Merkel, P.A., Smith, K.G.C., González-Gay, M.A., Martín, J. and Spanish Gca Study Group, U.K.G.C.A.C.T.T.S.G.V.C.R.C.I.S.G.A.A.V.S.g. Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis. *Ann Rheum Dis.* 2018, **77**, pp.589-595.
 10. Massey, J., Plant, D., Hyrich, K., **Morgan, A.W.**, Wilson, A.G., Spiliopoulou, A., Colombo, M., McKeigue, P., Isaacs, J., Cordell, H., Pitzalis, C., Barton, A. and Braggss, M.C. Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. *Pharmacogenomics J.* 2018, **18**, pp.657-664.
 11. González-Serna, D., Carmona, E.G., Ortego-Centeno, N., Simeón, C.P., Solans, R., Hernández-Rodríguez, J., Tolosa, C., Castañeda, S., Narváez, J., Martínez-Valle, F., European, G.C.A.C., European Scleroderma, G., Witte, T., Neumann, T., Holle, J., Beretta, L., Boiardi, L., Emmi, G., Cimmino, M.A., Vaglio, A., Herrick, A.L., Denton, C.P., Salvarani, C., Cid, M.C., **Morgan, A.W.**, Fonseca, C., González-Gay, M.A., Martín, J. and Márquez, A. A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. *PLoS One.* 2018, **13**, p.e0209343.
 12. Coath, F., Gillbert, K., Griffiths, B., Hall, F., Kay, L., Lanyon, P., Luqmani, R., Mackie, S.L., Mason, J.C., Mills, J., Mollan, S., **Morgan, A.W.**, Mukhtyar, C., Quick, V., Watts, R. and Dasgupta, B. Giant cell arteritis: new concepts, treatments and the unmet need that remains. *Rheumatology.* 2018, **58**, pp.1123-1125.
 13. Cherlin, S., Plant, D., Taylor, J.C., Colombo, M., Spiliopoulou, A., Tzanis, E., **Morgan, A.W.**, Barnes, M.R., McKeigue, P., Barrett, J.H., Pitzalis, C., Barton, A., Consortium, M. and Cordell, H.J. Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. *Genet Epidemiol.* 2018, **42**, pp.754-771.
- 2017**
14. Twigg, S., Hensor, E.M.A., Emery, P., Tennant, A., **Morgan, A.W.** and Yorkshire Early Arthritis Register, C. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. *J Rheumatol.* 2017, **44**, pp.1331-1340.
 15. Smith, S.L., Plant, D., Eyre, S., Hyrich, K., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D. and Barton, A. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. *Rheumatology (Oxford).* 2017, **56**, pp.1019-1024.
 16. Jani, M., Isaacs, J.D., **Morgan, A.W.**, Wilson, A.G., Plant, D., Hyrich, K.L., Chinoy, H., Barton, A. and Braggss. High frequency of antidrug antibodies and association of random

drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. *Ann Rheum Dis*. 2017, **76**, pp.208-213.

17. Clarke, K., Shastri, D., Chetcuti, P., Wood, M. and **Morgan, A.** Neonatal Behçet's disease. *Arch Dis Child*. 2017, **102**, pp.1062-1062.
18. Carmona, F.D., Vaglio, A., Mackie, S.L., Hernández-Rodríguez, J., Monach, P.A., Castañeda, S., Solans, R., Morado, I.C., Narváez, J., Ramentol-Sintas, M., Pease, C.T., Dasgupta, B., Watts, R., Khalidi, N., Langford, C.A., Ytterberg, S., Boiardi, L., Beretta, L., Govoni, M., Emmi, G., Bonatti, F., Cimmino, M.A., Witte, T., Neumann, T., Holle, J., Schönau, V., Sailler, L., Papo, T., Haroche, J., Mahr, A., Mouthon, L., Molberg, Ø., Diamantopoulos, A.P., Voskuyl, A., Brouwer, E., Daikeler, T., Berger, C.T., Molloy, E.S., O'Neill, L., Blockmans, D., Lie, B.A., McLaren, P., Vyse, T.J., Wijmenga, C., Allanore, Y., Koeleman, B.P.C., Spanish, C.G.A.G., Consortium, U., Vasculitis Clinical Research, C., Barrett, J.H., Cid, M.C., Salvarani, C., Merkel, P.A., **Morgan, A.W.**, González-Gay, M.A. and Martín, J. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. *Am J Hum Genet*. 2017, **100**, pp.64-74.

2016

19. Yarwood, A., Viatte, S., Okada, Y., Plenge, R., Yamamoto, K., Braggss, R., Barton, A., Symmons, D., Raychaudhuri, S., Klareskog, L., Gregersen, P., Worthington, J. and Eyre, S. Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study. *Ann Rheum Dis*. 2016, **75**, pp.317-320.
20. Smith, S.L., Plant, D., Lee, X.H., Massey, J., Hyrich, K., **Morgan, A.W.**, Wilson, A.G., Isaacs, J. and Barton, A. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. *Pharmacogenomics*. 2016, **17**, pp.715-720.
21. Plant, D., Webster, A., Nair, N., Oliver, J., Smith, S.L., Eyre, S., Hyrich, K.L., Wilson, A.G., **Morgan, A.W.**, Isaacs, J.D., Worthington, J. and Barton, A. Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. *Arthritis Rheumatol*. 2016, **68**, pp.1353-1360.
22. Nikiphorou, E., Mackie, S.L., Kirwan, J., Boers, M., Isaacs, J., **Morgan, A.W.***, Young, A*. Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. *Rheumatology*. 2016, **56**, pp.550-555.
23. Jani, M., Isaacs, J.D., **Morgan, A.W.**, Wilson, A.G., Plant, D., Hyrich, K.L., Chinoy, H. and Barton, A. Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. *Rheumatology (Oxford)*. 2016, **55**, pp.2050-2055.
24. Hernández-Rodríguez, J., Murgia, G., Villar, I., Campo, E., Mackie, S.L., Chakrabarty, A., Hensor, E.M.A., **Morgan, A.W.**, Font, C., Prieto-González, S., Espígol-Frigolé, G., Grau, J.M. and Cid, M.C. Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. *Medicine*. 2016, **95**, pp.e2368-e2368.
25. Bissell, L.-A., Hensor, E.M.A., Kozera, L., Mackie, S.L., Burska, A.N., Nam, J.L., Keen, H., Villeneuve, E., Donica, H., Buch, M.H., Conaghan, P.G., Andrews, J., Emery, P. and **Morgan, A.W.** Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis—results from the IDEA study. *Rheumatology*. 2016, **55**, pp.2181-2190.

2015

26. Vojdanian, M., Faezi, S.T., Tennant, A., **Morgan, A.W.**, Paragomi, P., Qorbani, M., Mattaji, M. and Davatchi, F. Validity and reliability of the Persian version of Behçet's disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation. *Rheumatol Int.* 2015, **35**, pp.677-684.
27. Viatte, S., Plant, D., Han, B., Fu, B., Yarwood, A., Thomson, W., Symmons, D.P.M., Worthington, J., Young, A., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Raychaudhuri, S. and Barton, A. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. *JAMA.* 2015, **313**, pp.1645-1656.
28. Smith, S.L., Eyre, S., Yarwood, A., Hyrich, K., **Morgan, A.W.**, Wilson, A.G., Isaacs, J., Biologics in Rheumatoid Arthritis, G., Genomics Study, S., Plant, D. and Barton, A. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. *Arthritis Res Ther.* 2015, **17**, pp.359-359.
29. Mackie, S.L., Taylor, J.C., Haroon-Rashid, L., Martin, S., Dasgupta, B., Gough, A., Green, M., Hordon, L., Jarrett, S., Pease, C.T., Barrett, J.H., Watts, R., **Morgan, A.W.**, Consortium, U.G. and Consortium, U. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. *Arthritis Res Ther.* 2015, **17**, p.195.
30. Jani, M., Chinoy, H., Warren, R.B., Griffiths, C.E.M., Plant, D., Fu, B., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Hyrich, K., Barton, A., Biologics in Rheumatoid Arthritis, G. and Genomics Study Syndicate, C. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. *Arthritis Rheumatol.* 2015, **67**, pp.2011-2019.
31. Donaldson, S.L., Cobine-Davies, M., **Morgan, A.W.**, Gough, A. and Mackie, S.L. Curry-assisted diagnosis in the rheumatology clinic. *Oxf Med Case Reports.* 2015, **2015**, pp.297-299.
32. Cortes, A., Maksymowych, W.P., Wordsworth, B.P., Inman, R.D., Danoy, P., Rahman, P., Stone, M.A., Corr, M., Gensler, L.S., Gladman, D., **Morgan, A.**, Marzo-Ortega, H., Ward, M.M., Sparcc, Tasc, Learch, T.J., Reveille, J.D., Brown, M.A*. and Weisman, M.H*. Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. *Ann Rheum Dis.* 2015, **74**, pp.1387-1393.
33. Carmona, F.D.*, Mackie, S.L.*, Martín, J.-E.*, Taylor, J.C., Vaglio, A., Eyre, S., Bossini-Castillo, L., Castañeda, S., Cid, M.C., Hernández-Rodríguez, J., Prieto-González, S., Solans, R., Ramentol-Sintas, M., González-Escribano, M.F., Ortiz-Fernández, L., Morado, I.C., Narváez, J., Miranda-Filloy, J.A., Spanish, G.C.A.G., Beretta, L., Lunardi, C., Cimmino, M.A., Gianfreda, D., Santilli, D., Ramirez, G.A., Soriano, A., Muratore, F., Pazzola, G., Addimanda, O., Wijmenga, C., Witte, T., Schirmer, J.H., Moosig, F., Schönau, V., Franke, A., Palm, Ø., Molberg, Ø., Diamantopoulos, A.P., Carette, S., Cuthbertson, D., Forbess, L.J., Hoffman, G.S., Khalidi, N.A., Koenig, C.L., Langford, C.A., McAlear, C.A., Moreland, L., Monach, P.A., Pagnoux, C., Seo, P., Spiera, R., Sreih, A.G., Warrington, K.J., Ytterberg, S.R., Gregersen, P.K., Pease, C.T., Gough, A., Green, M., Hordon, L., Jarrett, S., Watts, R., Levy, S., Patel, Y., Kamath, S., Dasgupta, B., Worthington, J., Koeleman, B.P.C., de Bakker, P.I.W., Barrett, J.H., Salvarani, C., Merkel, P.A., González-Gay, M.A., **Morgan, A.W.** and Martín, J. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. *Am J Hum Genet.* 2015, **96**, pp.565-580.

34. Bowes, J., Budu-Aggrey, A., Huffmeier, U., Uebe, S., Steel, K., Hebert, H.L., Wallace, C., Massey, J., Bruce, I.N., Bluett, J., Feletar, M., **Morgan, A.W.**, Marzo-Ortega, H., Donohoe, G., Morris, D.W., Helliwell, P., Ryan, A.W., Kane, D., Warren, R.B., Korendowych, E., Alenius, G.-M., Giardina, E., Packham, J., McManus, R., FitzGerald, O., McHugh, N., Brown, M.A., Ho, P., Behrens, F., Burkhardt, H., Reis, A. and Barton, A. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. *Nat Commun.* 2015, **6**, pp.6046-6046.

2014

35. Yarwood, A., Viatte, S., Plant, D., **Morgan, A.W.**, Isaacs, J., Wilson, A.G., Hyrich, K., Eyre, S. and Barton, A. Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. *Ann Rheum Dis.* 2014, **73**, pp.938-940.
36. Webster, A., Plant, D., Eyre, S., Wilson, G., **Morgan, A.**, Isaacs, J., Worthington, J. and Barton, A. OP0257 Differential DNA Methylation Related to Response to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. *Ann Rheum Dis.* 2014, **73**, pp.158-159.
37. Orozco, G., Viatte, S., Bowes, J., Martin, P., Wilson, A.G., **Morgan, A.W.**, Steer, S., Wordsworth, P., Hocking, L.J., Consortium, U.K.R.A.G., Wellcome Trust Case Control, C., Biologics in Rheumatoid Arthritis, G., Genomics Study Syndicate, C., Barton, A., Worthington, J. and Eyre, S. Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. *Arthritis Rheumatol.* 2014, **66**, pp.24-30.
38. Nam, J.L., Villeneuve, E., Hensor, E.M.A., Conaghan, P.G., Keen, H.I., Buch, M.H., Gough, A.K., Green, M.J., Helliwell, P.S., Keenan, A.M., **Morgan, A.W.**, Quinn, M., Reece, R., van der Heijde, D.M., Wakefield, R.J. and Emery, P. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). *Ann Rheum Dis.* 2014, **73**, pp.75-85.
39. Morgan, M.D., Al-Shaarawy, N., Martin, S., Robinson, J.I., Twigg, S., Consortium, Y., Magdy, A.A., Omar, A.S., Ghattas, M.H., Emery, P., Barrett, J.H. and **Morgan, A.W.** MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. *Pharmacogenomics.* 2014, **15**, pp.467-475.
40. Mathews, R.J., Robinson, J.I., Battellino, M., Wong, C., Taylor, J.C., Eyre, S., Churchman, S.M., Wilson, A.G., Isaacs, J.D., Hyrich, K., Barton, A., Plant, D., Savic, S., Cook, G.P., Sarzi-Puttini, P., Emery, P., Barrett, J.H., **Morgan, A.W.*** and McDermott, M.F*. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. *Ann Rheum Dis.* 2014, **73**, pp.1202-1210.
41. Mackie, S.L., Hensor, E.M.A., **Morgan, A.W.** and Pease, C.T. Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. *Ann Rheum Dis.* 2014, **73**, pp.143-148.
42. Cordingley, L., Prajapati, R., Plant, D., Maskell, D., Morgan, C., Ali, F.R., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Biologics in Rheumatoid Arthritis, G., Genomics Study, S. and Barton, A. Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. *Arthritis Care Res.* 2014, **66**, pp.861-868.
43. Bluett, J., Ibrahim, I., Plant, D., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Braggss and Barton, A. Association of a complement receptor 1 gene variant with

baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. *The pharmacogenomics journal*. 2014, **14**, pp.171-175.

44. Bluett, J., BRAGGSS, o.b.o., Morgan, C., BRAGGSS, o.b.o., Thurston, L., BRAGGSS, o.b.o., Plant, D., BRAGGSS, o.b.o., Hyrich, K.L., BRAGGSS, o.b.o., **Morgan, A.W.**, BRAGGSS, o.b.o., Wilson, A.G., BRAGGSS, o.b.o., Isaacs, J.D., BRAGGSS, o.b.o., Cordingley, L., BRAGGSS, o.b.o., Barton, A. and BRAGGSS, o.b.o. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. *Rheumatology*. 2014, **54**, pp.494-499.

2013

45. Teare, M.D., Knevel, R., Morgan, M.D., Kleszcz, A., Emery, P., Moore, D.J., Conaghan, P., Huizinga, T.W.J., **Morgan, A.W.**, van der Helm-van Mil, A.H.M. and Wilson, A.G. Allele-Dose Association of the C5orf30 rs26232 Variant With Joint Damage in Rheumatoid Arthritis. *Arthritis Rheum*. 2013, **65**, pp.2555-2561.
46. Taylor, L.H., Twigg, S., Worthington, J., Emery, P., **Morgan, A.W.**, Wilson, A.G. and Teare, M.D. Metaanalysis of the Association of Smoking and PTPN22 R620W Genotype on Autoantibody Status and Radiological Erosions in Rheumatoid Arthritis. *J Rheumatol*. 2013, **40**, pp.1048-1053.
47. Serrano, A.*, Márquez, A.*, Mackie, S.L.*, Carmona, F.D.*, Solans, R., Miranda-Fillo, J.A., Hernández-Rodríguez, J., Cid, M.C., Castañeda, S., Morado, I.C., Narváez, J., Blanco, R., Sopeña, B., García-Villanueva, M.J., Monfort, J., Ortego-Centeno, N., Unzurrunzaga, A., Marí-Alfonso, B., Sánchez Martín, J., de Miguel, E., Magro, C., Raya, E., Consortium, U.G., Spanish, G.C.A.C., Braun, N., Latus, J., Molberg, O., Lie, B.A., Moosig, F., Witte, T., **Morgan, A.W.**, González-Gay, M.A. and Martín, J. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. *Ann Rheum Dis*. 2013, **72**, pp.1882-1886.
48. Scott, I.C., Seegobin, S.D., Steer, S., Tan, R., Forabosco, P., Hinks, A., Eyre, S., **Morgan, A.W.**, Wilson, A.G., Hocking, L.J., Wordsworth, P., Barton, A., Worthington, J., Cope, A.P. and Lewis, C.M. Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. *PLoS Genet*. 2013, **9**, pp.e1003808-e1003808.
49. McAllister, K., Yarwood, A., Bowes, J., Orozco, G., Viatte, S., Diogo, D., Hocking, L.J., Steer, S., Wordsworth, P., Wilson, A.G., **Morgan, A.W.**, Consortium, U.K.R.A.G., Rheumatoid Arthritis Consortium, I., Kremer, J.M., Pappas, D., Gregersen, P., Klareskog, L., Plenge, R., Barton, A., Greenberg, J., Worthington, J. and Eyre, S. Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. *Arthritis Rheum*. 2013, **65**, pp.3058-3062.
50. International Genetics of Ankylosing Spondylitis, C., Cortes, A., Hadler, J., Pointon, J.P., Robinson, P.C., Karaderi, T., Leo, P., Cremin, K., Pryce, K., Harris, J., Lee, S., Joo, K.B., Shim, S.-C., Weisman, M., Ward, M., Zhou, X., Garchon, H.-J., Chiochia, G., Nossent, J., Lie, B.A., Førre, Ø., Tuomilehto, J., Laiho, K., Jiang, L., Liu, Y., Wu, X., Bradbury, L.A., Elewaut, D., Burgos-Vargas, R., Stebbings, S., Appleton, L., Farrah, C., Lau, J., Kenna, T.J., Haroon, N., Ferreira, M.A., Yang, J., Mulero, J., Fernandez-Sueiro, J.L., Gonzalez-Gay, M.A., Lopez-Larrea, C., Deloukas, P., Donnelly, P., Australo-Anglo-American Spondyloarthritis, C., Groupe Française d'Etude Génétique des, S., Nord-Trøndelag Health, S., Spondyloarthritis Research Consortium of, C., Wellcome Trust Case Control, C., Bowness, P., Gafney, K., Gaston, H., Gladman, D.D., Rahman, P.,

Maksymowych, W.P., Xu, H., Crusius, J.B.A., van der Horst-Bruinsma, I.E., Chou, C.-T., Valle-Oñate, R., Romero-Sánchez, C., Hansen, I.M., Pimentel-Santos, F.M., Inman, R.D., Videm, V., Martin, J., Breban, M., Reveille, J.D., Evans, D.M., Kim, T.-H., Wordsworth, B.P. and Brown, M.A. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet.* 2013, **45**, pp.730-738.

51. Cui, J., Stahl, E.A., Saevarsdottir, S., Miceli, C., Diogo, D., Trynka, G., Raj, T., Mirkov, M.U., Canhao, H., Ikari, K., Terao, C., Okada, Y., Wedrén, S., Askling, J., Yamanaka, H., Momohara, S., Taniguchi, A., Ohmura, K., Matsuda, F., Mimori, T., Gupta, N., Kuchroo, M., **Morgan, A.W.**, Isaacs, J.D., Wilson, A.G., Hyrich, K.L., Herenius, M., Doorenspleet, M.E., Tak, P.-P., Crusius, J.B.A., van der Horst-Bruinsma, I.E., Wolbink, G.J., van Riel, P.L.C.M., van de Laar, M., Guchelaar, H.-J., Shadick, N.A., Allaart, C.F., Huizinga, T.W.J., Toes, R.E.M., Kimberly, R.P., Bridges, S.L., Jr., Criswell, L.A., Moreland, L.W., Fonseca, J.E., de Vries, N., Stranger, B.E., De Jager, P.L., Raychaudhuri, S., Weinblatt, M.E., Gregersen, P.K., Mariette, X., Barton, A., Padyukov, L., Coenen, M.J.H., Karlson, E.W. and Plenge, R.M. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. *PLoS Genet.* 2013, **9**, pp.e1003394-e1003394.

2012

52. Zaitlen, N., Lindström, S., Pasaniuc, B., Cornelis, M., Genovese, G., Pollack, S., Barton, A., Bickeböller, H., Bowden, D.W., Eyre, S., Freedman, B.I., Friedman, D.J., Field, J.K., Groop, L., Haugen, A., Heinrich, J., Henderson, B.E., Hicks, P.J., Hocking, L.J., Kolonel, L.N., Landi, M.T., Langefeld, C.D., Le Marchand, L., Meister, M., **Morgan, A.W.**, Raji, O.Y., Risch, A., Rosenberger, A., Scherf, D., Steer, S., Walshaw, M., Waters, K.M., Wilson, A.G., Wordsworth, P., Zienoldiny, S., Tchetgen, E.T., Haiman, C., Hunter, D.J., Plenge, R.M., Worthington, J., Christiani, D.C., Schaumberg, D.A., Chasman, D.I., Altshuler, D., Voight, B., Kraft, P., Patterson, N. and Price, A.L. Informed Conditioning on Clinical Covariates Increases Power in Case-Control Association Studies. *PLoS Genet.* 2012, **8**, p.e1003032.
53. Robinson, J.I., Carr, I.M., Cooper, D.L., Rashid, L.H., Martin, S.G., Emery, P., Isaacs, J.D., Barton, A., BRAGGSS, Wilson, A.G., Barrett, J.H. and **Morgan, A.W.** Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. *Human Mutat.* 2012, **33**, pp.741-749.
54. Plant, D., Prajapati, R., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Biologics in Rheumatoid Arthritis, G., Genomics Study, S. and Barton, A. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. *Arthritis Rheum.* 2012, **64**, pp.665-670.
55. Plant, D., Ibrahim, I., Lunt, M., Eyre, S., Flynn, E., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Braggss and Barton, A. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. *Arthritis Res Ther.* 2012, **14**, pp.R214-R214.
56. Owen, R.L., Axford, D., Nettleship, J.E., Owens, R.J., Robinson, J.I., **Morgan, A.W.**, Doré, A.S., Lebon, G., Tate, C.G., Fry, E.E., Ren, J., Stuart, D.I. and Evans, G. Outrunning free radicals in room-temperature macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr.* 2012, **68**, pp.810-818.
57. Mackie, S.L., Taylor, J.C., Twigg, S., Martin, S.G., Steer, S., Worthington, J., Barton, A., Wilson, A.G., Hocking, L., Young, A., Emery, P., Barrett, J.H. and **Morgan, A.W.**

Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. *Ann Rheum Dis*. 2012, **71**, pp.1640-1645.

58. Hinks, A., Cobb, J., Sudman, M., Eyre, S., Martin, P., Flynn, E., Packham, J., Childhood Arthritis Prospective, S., Consortium, U.R.G., British Society of, P., Adolescent Rheumatology Study, G., Barton, A., Worthington, J., Langefeld, C.D., Glass, D.N., Thompson, S.D. and Thomson, W. Investigation of rheumatoid arthritis susceptibility loci in juvenile idiopathic arthritis confirms high degree of overlap. *Ann Rheum Dis*. 2012, **71**, pp.1117-1121.
59. Coulthard, L.R., Geiler, J., Mathews, R.J., Church, L.D., Dickie, L.J., Cooper, D.L., Wong, C., Savic, S., Bryer, D., Buch, M.H., Emery, P., **Morgan, A.W.** and McDermott, M.F. Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. *Clin Exp Immunol*. 2012, **170**, pp.36-46.
60. Cooper, D.L., Martin, S.G., Robinson, J.I., Mackie, S.L., Charles, C.J., Nam, J., Consortium, Y., Isaacs, J.D., Emery, P. and **Morgan, A.W.** FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. *PLoS one*. 2012, **7**, pp.e28918-e28918.
61. Bowes, J., Ho, P., Flynn, E., Salah, S., McHugh, N., FitzGerald, O., Packham, J., **Morgan, A.W.**, Helliwell, P.S., Bruce, I.N. and Barton, A. Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. *Ann Rheum Dis*. 2012, **71**, pp.313-314.
62. Bowes, J., Ho, P., Flynn, E., Ali, F., Marzo-Ortega, H., Coates, L.C., Warren, R.B., McManus, R., Ryan, A.W., Kane, D., Korendowych, E., McHugh, N., FitzGerald, O., Packham, J., **Morgan, A.W.**, Bruce, I.N. and Barton, A. Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. *Ann Rheum Dis*. 2012, **71**, pp.1350-1354.
63. Axford, D., Owen, R.L., Aishima, J., Foadi, J., **Morgan, A.W.**, Robinson, J.I., Nettleship, J.E., Owens, R.J., Moraes, I., Fry, E.E., Grimes, J.M., Harlos, K., Kotecha, A., Ren, J., Sutton, G., Walter, T.S., Stuart, D.I. and Evans, G. In situ macromolecular crystallography using microbeams. *Acta Crystallogr D Biol Crystallogr*. 2012, **68**, pp.592-600.

2011

64. Warren, R.B., Smith, R.L., Flynn, E., Bowes, J., Consortium, U., Eyre, S., Worthington, J., Barton, A. and Griffiths, C.E.M. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. *Brit J Dermatol*. 2011, **164**, pp.660-664.
65. Plant, D., Bowes, J., Potter, C., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Wellcome Trust Case Control, C., British Society for Rheumatology Biologics, R. and Barton, A. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. *Arthritis Rheum*. 2011, **63**, pp.645-653.
66. Orozco, G., Eyre, S., Hinks, A., Bowes, J., **Morgan, A.W.**, Wilson, A.G., Wordsworth, P., Steer, S., Hocking, L., Thomson, W., Worthington, J. and Barton, A. Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis*. 2011, **70**, pp.463-468.

67. Mackie, S.L., Taylor, J.C., Martin, S.G., Consortium, Y., Consortium, U., Wordsworth, P., Steer, S., Wilson, A.G., Worthington, J., Emery, P., Barrett, J.H. and **Morgan, A.W.** A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. *Genes Immun.* 2011, **13**, p.120.
68. Mackie, S.L., Consortium, o.b.o.t.U.G., Dasgupta, B., Consortium, o.b.o.t.U.G., Hordon, L., Consortium, o.b.o.t.U.G., Gough, A., Consortium, o.b.o.t.U.G., Green, M., Consortium, o.b.o.t.U.G., Hollywood, J., Consortium, o.b.o.t.U.G., Dutta, S., Consortium, o.b.o.t.U.G., Bejarano, V., Consortium, o.b.o.t.U.G., Jarrett, S., Consortium, o.b.o.t.U.G., **Morgan, A.W.**, Consortium, o.b.o.t.U.G., Pease, C.T. and Consortium, o.b.o.t.U.G. Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. *Rheumatology.* 2011, **50**, pp.2014-2022.
69. Kozera, L., Andrews, J. and **Morgan, A.W.** Cardiovascular risk and rheumatoid arthritis—the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. *Rheumatology.* 2011, **50**, pp.1944-1954.
70. Hinks, A., Eyre, S., Martin, P., Flynn, E., Packham, J., Barton, A., Worthington, J. and Thomson, W. Rheumatoid Arthritis susceptibility loci; PTPRC, PTPN2, IKZE3, c5orf30, BLK and CD247 are also associated with Juvenile Idiopathic Arthritis. *Clin Exp Rheumatol.* 2011, **29**, pp.374-375.
71. Evans, D.M., Spencer, C.C.A., Pointon, J.J., Su, Z., Harvey, D., Kochan, G., Oppermann, U., Dilthey, A., Pirinen, M., Stone, M.A., Appleton, L., Moutsianas, L., Leslie, S., Wordsworth, T., Kenna, T.J., Karaderi, T., Thomas, G.P., Ward, M.M., Weisman, M.H., Farrar, C., Bradbury, L.A., Danoy, P., Inman, R.D., Maksymowych, W., Gladman, D., Rahman, P., Spondyloarthritis Research Consortium of, C., **Morgan, A.**, Marzo-Ortega, H., Bowness, P., Gaffney, K., Gaston, J.S.H., Smith, M., Bruges-Armas, J., Couto, A.-R., Sorrentino, R., Paladini, F., Ferreira, M.A., Xu, H., Liu, Y., Jiang, L., Lopez-Larrea, C., Díaz-Peña, R., López-Vázquez, A., Zayats, T., Band, G., Bellenguez, C., Blackburn, H., Blackwell, J.M., Bramon, E., Bumpstead, S.J., Casas, J.P., Corvin, A., Craddock, N., Deloukas, P., Dronov, S., Duncanson, A., Edkins, S., Freeman, C., Gillman, M., Gray, E., Gwilliam, R., Hammond, N., Hunt, S.E., Jankowski, J., Jayakumar, A., Langford, C., Liddle, J., Markus, H.S., Mathew, C.G., McCann, O.T., McCarthy, M.I., Palmer, C.N.A., Peltonen, L., Plomin, R., Potter, S.C., Rautanen, A., Ravindrarajah, R., Ricketts, M., Samani, N., Sawcer, S.J., Strange, A., Trembath, R.C., Viswanathan, A.C., Waller, M., Weston, P., Whittaker, P., Widaa, S., Wood, N.W., McVean, G., Reveille, J.D., Wordsworth, B.P., Brown, M.A., Donnelly, P., Australo-Anglo-American Spondyloarthritis, C. and Wellcome Trust Case Control, C. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet.* 2011, **43**, pp.761-767.
72. Coulthard, L.R., Taylor, J.C., Eyre, S., Robinson, J.I., Wilson, A.G., Isaacs, J.D., Hyrich, K., Emery, P., Barton, A., Barrett, J.H., **Morgan, A.W.** and McDermott, M.F. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. *Ann Rheum Dis.* 2011, **70**, pp.98-103.
73. Bowes, J., Orozco, G., Flynn, E., Ho, P., Brier, R., Marzo-Ortega, H., Coates, L., McManus, R., Ryan, A.W., Kane, D., Korendowych, E., McHugh, N., FitzGerald, O., Packham, J., **Morgan, A.W.**, Bruce, I.N. and Barton, A. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. *Ann Rheum Dis.* 2011, **70**, pp.1641-1644.
74. Bowes, J., Eyre, S., Flynn, E., Ho, P., Salah, S., Warren, R.B., Marzo-Ortega, H., Coates, L., McManus, R., Ryan, A.W., Kane, D., Korendowych, E., McHugh, N., FitzGerald, O., Packham, J., **Morgan, A.W.**, Griffiths, C.E.M., Bruce, I.N., Worthington, J. and Barton, A. Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. *Ann Rheum Dis.* 2011, **70**, pp.1016-1019.

75. Wellcome Trust Case Control, C., Craddock, N., Hurles, M.E., Cardin, N., Pearson, R.D., Plagnol, V., Robson, S., Vukcevic, D., Barnes, C., Conrad, D.F., Giannoulatou, E., Holmes, C., Marchini, J.L., Stirrups, K., Tobin, M.D., Wain, L.V., Yau, C., Aerts, J., Ahmad, T., Andrews, T.D., Arbury, H., Attwood, A., Auton, A., Ball, S.G., Balmforth, A.J., Barrett, J.C., Barroso, I., Barton, A., Bennett, A.J., Bhaskar, S., Blaszczyk, K., Bowes, J., Brand, O.J., Braund, P.S., Bredin, F., Breen, G., Brown, M.J., Bruce, I.N., Bull, J., Burren, O.S., Burton, J., Byrnes, J., Caesar, S., Clee, C.M., Coffey, A.J., Connell, J.M.C., Cooper, J.D., Dominicczak, A.F., Downes, K., Drummond, H.E., Dudakia, D., Dunham, A., Ebbs, B., Eccles, D., Edkins, S., Edwards, C., Elliot, A., Emery, P., Evans, D.M., Evans, G., Eyre, S., Farmer, A., Ferrier, I.N., Feuk, L., Fitzgerald, T., Flynn, E., Forbes, A., Forty, L., Franklyn, J.A., Freathy, R.M., Gibbs, P., Gilbert, P., Gokumen, O., Gordon-Smith, K., Gray, E., Green, E., Groves, C.J., Grozeva, D., Gwilliam, R., Hall, A., Hammond, N., Hardy, M., Harrison, P., Hassanali, N., Hebaishi, H., Hines, S., Hinks, A., Hitman, G.A., Hocking, L., Howard, E., Howard, P., Howson, J.M.M., Hughes, D., Hunt, S., Isaacs, J.D., Jain, M., Jewell, D.P., Johnson, T., Jolley, J.D., Jones, I.R., Jones, L.A., Kirov, G., Langford, C.F., Lango-Allen, H., Lathrop, G.M., Lee, J., Lee, K.L., Lees, C., Lewis, K., Lindgren, C.M., Maisuria-Armer, M., Maller, J., Mansfield, J., Martin, P., Massey, D.C.O., McArdle, W.L., McGuffin, P., McLay, K.E., Mentzer, A., Mimmack, M.L., **Morgan, A.W.**, Morris, A.P., Mowat, C., Myers, S., Newman, W., Nimmo, E.R., O'Donovan, M.C., Onipinla, A., Onyiah, I., Ovington, N.R., Owen, M.J., Palin, K., Parnell, K., Pernet, D., Perry, J.R.B., Phillips, A., Pinto, D., Prescott, N.J., Prokopenko, I., Quail, M.A., Rafelt, S., Rayner, N.W., Redon, R., Reid, D.M., Renwick, Ring, S.M., Robertson, N., Russell, E., St Clair, D., Sambrook, J.G., Sanderson, J.D., Schuilenburg, H., Scott, C.E., Scott, R., Seal, S., Shaw-Hawkins, S., Shields, B.M., Simmonds, M.J., Smyth, D.J., Somaskantharajah, E., Spanova, K., Steer, S., Stephens, J., Stevens, H.E., Stone, M.A., Su, Z., Symmons, D.P.M., Thompson, J.R., Thomson, W., Travers, M.E., Turnbull, C., Valsesia, A., Walker, M., Walker, N.M., Wallace, C., Warren-Perry, M., Watkins, N.A., Webster, J., Weedon, M.N., Wilson, A.G., Woodburn, M., Wordsworth, B.P., Young, A.H., Zeggini, E., Carter, N.P., Frayling, T.M., Lee, C., McVean, G., Munroe, P.B., Palotie, A., Sawcer, S.J., Scherer, S.W., Strachan, D.P., Tyler-Smith, C., Brown, M.A., Burton, P.R., Caulfield, M.J., Compston, A., Farrall, M., Gough, S.C.L., Hall, A.S., Hattersley, A.T., Hill, A.V.S., Mathew, C.G., Pembrey, M., Satsangi, J., Stratton, M.R., Worthington, J., Deloukas, P., Duncanson, A., Kwiatkowski, D.P., McCarthy, M.I., Ouwehand, W., Parkes, M., Rahman, N., Todd, J.A., Samani, N.J. and Donnelly, P. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature*. 2010, **464**, pp.713-720.
76. Tan, R.J.L., Gibbons, L.J., Potter, C., Hyrich, K.L., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Braggss and Barton, A. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. *Ann Rheum Dis*. 2010, **69**, pp.1029-1035.
77. Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Li, Y., Kurreeman, F.A.S., Zhernakova, A., Hinks, A., Guiducci, C., Chen, R., Alfredsson, L., Amos, C.I., Ardlie, K.G., Consortium, B., Barton, A., Bowes, J., Brouwer, E., Burt, N.P., Catanese, J.J., Coblyn, J., Coenen, M.J.H., Costenbader, K.H., Criswell, L.A., Crusius, J.B.A., Cui, J., de Bakker, P.I.W., De Jager, P.L., Ding, B., Emery, P., Flynn, E., Harrison, P., Hocking, L.J., Huizinga, T.W.J., Kastner, D.L., Ke, X., Lee, A.T., Liu, X., Martin, P., **Morgan, A.W.**, Padyukov, L., Posthumus, M.D., Radstake, T.R.D.J., Reid, D.M., Seielstad, M., Seldin, M.F., Shadick, N.A., Steer, S., Tak, P.P., Thomson, W., van der Helm-van Mil, A.H.M., van der Horst-Bruinsma, I.E., van der Schoot, C.E., van Riel, P.L.C.M., Weinblatt, M.E., Wilson, A.G., Wolbink, G.J., Wordsworth, B.P., Consortium, Y., Wijmenga, C., Karlson, E.W., Toes, R.E.M., de Vries, N., Begovich, A.B., Worthington, J., Siminovitch, K.A., Gregersen, P.K., Klareskog, L. and Plenge, R.M.

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat genet.* 2010, **42**, pp.508-514.

78. Robinson, J.I., Barrett, J.H., Taylor, J.C., Naven, M., Corscadden, D., Barton, A., Wilson, A.G., Emery, P., Isaacs, J.D. and **Morgan, A.W.** Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. *Ann Rheum Dis.* 2010, **69**, pp.1054-1057.
79. Potter, C., Gibbons, L.J., Bowes, J.D., Cordell, H.J., Hyrich, K., Isaacs, J.D., **Morgan, A.W.**, Wilson, A.G., Barton, A., Genetics, o.b.o.B.i.R.A. and Syndicate, G.S. Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. *Pharmacogenet Genom.* 2010, **20**, pp.338-341.
80. Potter, C., Cordell, H.J., Barton, A., Daly, A.K., Hyrich, K.L., Mann, D.A., **Morgan, A.W.**, Wilson, A.G. and Isaacs, J.D. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathways. *Ann Rheum Dis.* 2010, **69**, pp.1315-1320.
81. Orozco, G., Eyre, S., Hinks, A., Ke, X., Wellcome Trust Case Control consortium, Y.C., Wilson, A.G., Bax, D.E., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P., Thomson, W., Barton, A. and Worthington, J. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. *Ann Rheum Dis.* 2010, **69**, pp.813-816.
82. **Morgan, A.W.**, Robinson, J.I., Conaghan, P.G., Martin, S.G., Hensor, E.M.A., Morgan, M.D., Steiner, L., Erlich, H.A., Gooi, H.-C., Barton, A., Worthington, J., Emery, P., Consortium, U. and Consortium, Y. Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. *Arthritis Res Ther.* 2010, **12**, pp.R57-R57.
83. Hinks, A., Martin, P., Flynn, E., Eyre, S., Packham, J., Childhood Arthritis Prospective Study, U.C.B.S.G., Barton, A., Worthington, J. and Thomson, W. Association of the CCR5 gene with juvenile idiopathic arthritis. *Genes Immun.* 2010, **11**, pp.584-589.
84. Hinks, A., Martin, P., Flynn, E., Eyre, S., Packham, J., Barton, A., Childhood Arthritis Prospective Study, U.C.B.s.g., Worthington, J. and Thomson, W. Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. *Ann Rheum Dis.* 2010, **69**, pp.2169-2172.
85. Hinks, A., Eyre, S., Ke, X., Barton, A., Martin, P., Flynn, E., Packham, J., Worthington, J., Childhood Arthritis Prospective, S., Consortium, U., Group, B.S. and Thomson, W. Association of the AFF3 gene and IL2/IL21 gene region with juvenile idiopathic arthritis. *Gen Immun.* 2010, **11**, pp.194-198.
86. Hinks, A., Eyre, S., Ke, X., Barton, A., Martin, P., Flynn, E., Packham, J., Childhood Arthritis Prospective, S., Consortium, U., Group, B.S., Worthington, J. and Thomson, W. Overlap of disease susceptibility loci for rheumatoid arthritis and juvenile idiopathic arthritis. *Ann Rheum Dis.* 2010, **69**, pp.1049-1053.
87. Hensor, E.M.A., Emery, P., Bingham, S.J., Conaghan, P.G. and *, t.Y.C. Discrepancies in categorizing rheumatoid arthritis patients by DAS-28(ESR) and DAS-28(CRP): can they be reduced? *Rheumatology.* 2010, **49**, pp.1521-1529.
88. Eyre, S., Hinks, A., Flynn, E., Martin, P., Wilson, A.G., Maxwell, J.R., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L.J., Reid, D.M., Harrison, P., Wordsworth, P., Thomson, W., Worthington, J. and Barton, A. Confirmation of association of the REL locus with

rheumatoid arthritis susceptibility in the UK population. *Ann Rheum Dis.* 2010, **69**, pp.1572-1573.

89. Eyre, S., Hinks, A., Bowes, J., Flynn, E., Martin, P., Wilson, A.G., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L.J., Reid, D.M., Harrison, P., Wordsworth, P., Yorkshire Early Arthritis, C., Biologics in, R.A.C.C., Thomson, W., Worthington, J. and Barton, A. Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. *Arthritis Res Ther.* 2010, **12**, pp.R175-R175.
90. Eyre, S., Flynn, E., Martin, P., Hinks, A., Wilson, A.G., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L.J., Reid, D.M., Harrison, P., Wordsworth, P., Thomson, W., Worthington, J. and Barton, A. No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. *Ann Rheum Dis.* 2010, **69**, pp.1407-1408.
91. Cui, J., Saevarsdottir, S., Thomson, B., Padyukov, L., van der Helm-van Mil, A.H.M., Nititham, J., Hughes, L.B., de Vries, N., Raychaudhuri, S., Alfredsson, L., Askling, J., Wedrén, S., Ding, B., Guiducci, C., Wolbink, G.J., Crusius, J.B.A., van der Horst-Bruinsma, I.E., Herenius, M., Weinblatt, M.E., Shadick, N.A., Worthington, J., Batliwalla, F., Kern, M., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Hyrich, K., Seldin, M.F., Moreland, L.W., Behrens, T.W., Allaart, C.F., Criswell, L.A., Huizinga, T.W.J., Tak, P.P., Bridges, S.L., Jr., Toes, R.E.M., Barton, A., Klareskog, L., Gregersen, P.K., Karlson, E.W. and Plenge, R.M. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. *Arthritis Rheum.* 2010, **62**, pp.1849-1861.
92. Conaghan, P.G., Hensor, E.M.A., Keenan, A.-M., **Morgan, A.W.**, Emery, P. and Consortium, t.Y. Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. *Rheumatology.* 2010, **49**, pp.1894-1899.
93. Burr, M.L., Naseem, H., Hinks, A., Eyre, S., Gibbons, L.J., Bowes, J., Wilson, A.G., Maxwell, J., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P., Thomson, W., Worthington, J., Consortium, B., Consortium, Y. and Barton, A. PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. *Ann Rheum Dis.* 2010, **69**, pp.666-670.
94. Bowes, J., Lawrence, R., Eyre, S., Panoutsopoulou, K., Orozco, G., Elliott, K.S., Ke, X., Morris, A.P., Ukrag, Thomson, W., Worthington, J., Barton, A. and Zeggini, E. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. *Hum Genet.* 2010, **128**, pp.627-633.
95. Bowes, J., Flynn, E., Ho, P., Aly, B., **Morgan, A.W.**, Marzo-Ortega, H., Coates, L., McManus, R., Ryan, A.W., Kane, D., Korendowych, E., McHugh, N., FitzGerald, O., Packham, J., Bruce, I.N. and Barton, A. Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. *Ann Rheum Dis.* 2010, **69**, pp.2199-2203.

2009

96. Raychaudhuri, S., Thomson, B.P., Remmers, E.F., Eyre, S., Hinks, A., Guiducci, C., Catanese, J.J., Xie, G., Stahl, E.A., Chen, R., Alfredsson, L., Amos, C.I., Ardlie, K.G., Consortium, B., Barton, A., Bowes, J., Burtt, N.P., Chang, M., Coblyn, J., Costenbader, K.H., Criswell, L.A., Crusius, J.B.A., Cui, J., De Jager, P.L., Ding, B., Emery, P., Flynn, E., Harrison, P., Hocking, L.J., Huizinga, T.W.J., Kastner, D.L., Ke, X., Kurreeman, F.A.S., Lee, A.T., Liu, X., Li, Y., Martin, P., **Morgan, A.W.**, Padyukov, L., Reid, D.M., Seielstad, M., Seldin, M.F., Shadick, N.A., Steer, S., Tak, P.P., Thomson, W., van der Helm-van Mil, A.H.M., van der Horst-Bruinsma, I.E., Weinblatt, M.E., Wilson, A.G.,

- Wolbink, G.J., Wordsworth, P., Consortium, Y., Altshuler, D., Karlson, E.W., Toes, R.E.M., de Vries, N., Begovich, A.B., Siminovitch, K.A., Worthington, J., Klareskog, L., Gregersen, P.K., Daly, M.J. and Plenge, R.M. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. *Nat Genet.* 2009, **41**, pp.1313-1318.
97. Potter, C., Hyrich, K.L., Tracey, A., Lunt, M., Plant, D., Symmons, D.P.M., Thomson, W., Worthington, J., Emery, P., **Morgan, A.W.**, Wilson, A.G., Isaacs, J., Barton, A. and Braggss. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. *Ann Rheum Dis.* 2009, **68**, pp.69-74.
98. Plant, D., Barton, A., Thomson, W., Ke, X., Eyre, S., Hinks, A., Bowes, J., Gibbons, L.J., Wilson, A.G., Marinou, I., **Morgan, A.W.**, Steer, S., Hocking, L.J., Reid, D.M., Wordsworth, P., Harrison, P. and Worthington, J. A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. *Ann Rheum Dis.* 2009, **68**, pp.1373-1375.
99. Orozco, G., Hinks, A., Eyre, S., Ke, X., Gibbons, L.J., Bowes, J., Flynn, E., Martin, P., Wellcome Trust Case Control, C., consortium, Y., Wilson, A.G., Bax, D.E., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P., Thomson, W., Barton, A. and Worthington, J. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. *Hum Mol Genet.* 2009, **18**, pp.2693-2699.
100. **Morgan, A.W.**, Thomson, W., Martin, S.G., Consortium, Y.E.A.R., Carter, A.M., Consortium, U.R.A.G., Erlich, H.A., Barton, A., Hocking, L., Reid, D.M., Harrison, P., Wordsworth, P., Steer, S., Worthington, J., Emery, P., Wilson, A.G. and Barrett, J.H. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. *Arthritis Rheum.* 2009, **60**, pp.2565-2576.
101. McClure, A., Lunt, M., Eyre, S., Ke, X., Thomson, W., Hinks, A., Bowes, J., Gibbons, L., Plant, D., Wilson, A.G., Marinou, I., **Morgan, A.W.**, Emery, P., consortium, B., Steer, S., Hocking, L.J., Reid, D.M., Wordsworth, P., Harrison, P., Worthington, J. and Barton, A. Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. *Rheumatology (Oxford).* 2009, **48**, pp.1369-1374.
102. Hinks, A., Ke, X., Barton, A., Eyre, S., Bowes, J., Worthington, J., Thompson, S.D., Langefeld, C.D., Glass, D.N., Thomson, W., Consortium, U.K.R.A.G., British Society of P. and Adolescent Rheumatology Study, G. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. *Arthritis Rheum.* 2009, **60**, pp.251-257.
103. Hassan, B., Maxwell, J.R., Hyrich, K.L., Genetics, B.i.R.A., Syndicate, G.S., Barton, A., Worthington, J., Isaacs, J.D., **Morgan, A.W.** and Wilson, A.G. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. *Rheumatology.* 2009, **49**, pp.43-47.
104. Carr, I.M., Robinson, J.I., Dimitriou, R., Markham, A.F., **Morgan, A.W.** and Bonthron, D.T. Inferring relative proportions of DNA variants from sequencing electropherograms. *Bioinformatics.* 2009, **25**, pp.3244-3250.
105. Bowes, J.D., Potter, C., Gibbons, L.J., Hyrich, K., Plant, D., **Morgan, A.W.**, Wilson, A.G., Isaacs, J.D., Worthington, J., Barton, A. and BRAGGSS. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-

TNF agents in a UK cohort of rheumatoid arthritis patients. *Pharmacogenet Genom.* 2009, **19**, pp.319-323.

106. Barton, A., Eyre, S., Ke, X., Hinks, A., Bowes, J., Flynn, E., Martin, P., Consortium, Y., Consortium, B., Wilson, A.G., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L.J., Reid, D.M., Harrison, P., Wordsworth, P., Thomson, W. and Worthington, J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. *Hum Mol Genet.* 2009, **18**, pp.2518-2522.

2008

107. Willcocks, L.C., Lyons, P.A., Clatworthy, M.R., Robinson, J.I., Yang, W., Newland, S.A., Plagnol, V., McGovern, N.N., Condliffe, A.M., Chilvers, E.R., Adu, D., Jolly, E.C., Watts, R., Lau, Y.L., **Morgan, A.W.**, Nash, G. and Smith, K.G.C. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. *J Exp Med.* 2008, **205**, pp.1573-1582.
108. Pease, C.T., Haugeberg, G., Montague, B., Hensor, E.M.A., Bhakta, B.B., Thomson, W., Ollier, W.E.R. and **Morgan, A.W.** Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. *Rheumatology.* 2008, **48**, pp.123-127.
109. **Morgan, A.W.**, Haroon-Rashid, L., Martin, S.G., Gooi, H.-C., Worthington, J., Thomson, W., Barrett, J.H. and Emery, P. The shared epitope hypothesis in rheumatoid arthritis: Evaluation of alternative classification criteria in a large UK Caucasian cohort. *Arthritis Rheum.* 2008, **58**, pp.1275-1283.
110. **Morgan, A.W.**, Hale, G., Rebello, P.R.U.B., Richards, S.J., Gooi, H.-C., Waldmann, H., Emery, P. and Isaacs, J.D. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. *QJM Int J Med.* 2008, **101**, pp.299-306.
111. Maxwell, J.R., Potter, C., Hyrich, K.L., BRAGGSS, Barton, A., Worthington, J., Isaacs, J.D., **Morgan, A.W.** and Wilson, A.G. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet.* 2008, **17**, pp.3532-3538.
112. Linsel-Nitschke, P., Götz, A., Erdmann, J., Braenne, I., Braund, P., Hengstenberg, C., Stark, K., Fischer, M., Schreiber, S., El Mokhtari, N.E., Schaefer, A., Schrezenmeir, J., Rubin, D., Hinney, A., Reinehr, T., Roth, C., Ortlepp, J., Hanrath, P., Hall, A.S., Mangino, M., Lieb, W., Lamina, C., Heid, I.M., Doering, A., Gieger, C., Peters, A., Meitinger, T., Wichmann, H.E., König, I.R., Ziegler, A., Kronenberg, F., Samani, N.J., Schunkert, H., Wellcome Trust Case Control, C. and Cardiogenics, C. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. *PloS one.* 2008, **3**, pp.e2986-e2986.
113. Barton, A., Thomson, W., Ke, X., Eyre, S., Hinks, A., Bowes, J., Plant, D., Gibbons, L.J., Wellcome Trust Case Control, C., Consortium, Y., Consortium, B., Wilson, A.G., Bax, D.E., **Morgan, A.W.**, Emery, P., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P. and Worthington, J. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. *Nat Genet.* 2008, **40**, pp.1156-1159.
114. Barton, A., Thomson, W., Ke, X., Eyre, S., Hinks, A., Bowes, J., Gibbons, L., Plant, D., Wellcome Trust Case Control, C., Wilson, A.G., Marinou, I., **Morgan, A.**, Emery, P., consortium, Y., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P. and Worthington, J. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the

post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. *Hum Mol Genet.* 2008, **17**, pp.2274-2279.

2007

115. Zeggini, E., Weedon, M.N., Lindgren, C.M., Frayling, T.M., Elliott, K.S., Lango, H., Timpson, N.J., Perry, J.R.B., Rayner, N.W., Freathy, R.M., Barrett, J.C., Shields, B., Morris, A.P., Ellard, S., Groves, C.J., Harries, L.W., Marchini, J.L., Owen, K.R., Knight, B., Cardon, L.R., Walker, M., Hitman, G.A., Morris, A.D., Doney, A.S.F., Wellcome Trust Case Control, C., McCarthy, M.I. and Hattersley, A.T. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science.* 2007, **316**, pp.1336-1341.
116. Wellcome Trust Case Control, C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007, **447**, pp.661-678.
117. Todd, J.A., Walker, N.M., Cooper, J.D., Smyth, D.J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., Field, S.F., Payne, F., Lowe, C.E., Szeszkó, J.S., Hafler, J.P., Zeitels, L., Yang, J.H.M., Vella, A., Nutland, S., Stevens, H.E., Schuilenburg, H., Coleman, G., Maisuria, M., Meadows, W., Smink, L.J., Healy, B., Burren, O.S., Lam, A.A.C., Ovington, N.R., Allen, J., Adlem, E., Leung, H.-T., Wallace, C., Howson, J.M.M., Guja, C., Ionescu-Tîrgoviște, C., Genetics of Type 1 Diabetes in, F., Simmonds, M.J., Heward, J.M., Gough, S.C.L., Wellcome Trust Case Control, C., Dunger, D.B., Wicker, L.S. and Clayton, D.G. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet.* 2007, **39**, pp.857-864.
118. Thomson, W., Barton, A., Ke, X., Eyre, S., Hinks, A., Bowes, J., Donn, R., Symmons, D., Hider, S., Bruce, I.N., Wellcome Trust Case Control, C., Wilson, A.G., Marinou, I., **Morgan, A.**, Emery, P., Consortium, Y., Carter, A., Steer, S., Hocking, L., Reid, D.M., Wordsworth, P., Harrison, P., Strachan, D. and Worthington, J. Rheumatoid arthritis association at 6q23. *Nat Genet.* 2007, **39**, pp.1431-1433.
119. Parkes, M., Barrett, J.C., Prescott, N.J., Tremelling, M., Anderson, C.A., Fisher, S.A., Roberts, R.G., Nimmo, E.R., Cummings, F.R., Soars, D., Drummond, H., Lees, C.W., Khawaja, S.A., Bagnall, R., Burke, D.A., Todhunter, C.E., Ahmad, T., Onnie, C.M., McArdle, W., Strachan, D., Bethel, G., Bryan, C., Lewis, C.M., Deloukas, P., Forbes, A., Sanderson, J., Jewell, D.P., Satsangi, J., Mansfield, J.C., Wellcome Trust Case Control, C., Cardon, L. and Mathew, C.G. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. *Nat Genet.* 2007, **39**, pp.830-832.
120. **Morgan, A.W.**, Pearson, S.B., Davies, S., Gooi, H.C. and Bird, H.A. Asthma and airways collapse in two heritable disorders of connective tissue. *Ann Rheum Dis.* 2007, **66**, pp.1369-1373.
121. El-Sherbiny, Y.M., Meade, J.L., Holmes, T.D., McGonagle, D., Mackie, S.L., **Morgan, A.W.**, Cook, G., Feyler, S., Richards, S.J., Davies, F.E., Morgan, G.J. and Cook, G.P. The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. *Cancer Research.* 2007, **67**, pp.8444-8449.

2006

122. **Morgan, A.W.**, Robinson, J.I., Barrett, J.H., Martin, J., Walker, A., Babbage, S.J., Ollier, W.E.R., Gonzalez-Gay, M.A. and Isaacs, J.D. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. *Arthritis Res Ther.* 2006, **8**, pp.R109-R109.

123. **Morgan, A.W.**, Barrett, J.H., Griffiths, B., Subramanian, D., Robinson, J.I., Keyte, V.H., Ali, M., Jones, E.A., Old, R.W., Ponchel, F., Boylston, A.W., Situnayake, R.D., Markham, A.F., Emery, P. and Isaacs, J.D. Analysis of Fc γ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. *Arthritis Res Ther.* 2006, **8**, pp.R5-R5.

2005

124. Ponchel, F., Verburg, R.J., Bingham, S.J., Brown, A.K., Moore, J., Protheroe, A., Short, K., Lawson, C.A., **Morgan, A.W.**, Quinn, M., Buch, M., Field, S.L., Maltby, S.L., Masurel, A., Douglas, S.H., Straszynski, L., Fearon, U., Veale, D.J., Patel, P., McGonagle, D., Snowden, J., Markham, A.F., Ma, D., van Laar, J.M., Papadaki, H.A., Emery, P. and Isaacs, J.D. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. *Arthritis Res Ther.* 2005, **7**, pp.R80-R92.
125. Pease, C.T., Haugeberg, G., **Morgan, A.W.**, Montague, B., Hensor, E.M.A. and Bhakta, B.B. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. *J Rheumatol.* 2005, **32**, pp.1043-1046.
126. Lawson, C.A., Donaldson, I.J., Bowman, S.J., Shefta, J., **Morgan, A.W.**, Gough, A., Isaacs, J.D., Griffiths, B., Emery, P., Pease, C.T. and Boylston, A.W. Analysis of the insertion/deletion related polymorphism within T cell antigen receptor β variable genes in primary Sjögren's syndrome. *Ann Rheum Dis.* 2005, **64**, pp.468-470.

2004

127. **Morgan, A.**, Emery, P. and Isaacs, J. Fc gamma receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al. *Arthritis Rheum.* 2004, **50**, pp.1352-1353; author reply 1353.

2003

128. **Morgan, A.**, H Keyte, V., J Babbage, S., Robinson, J., Ponchel, F., Barrett, J., B Bhakta, B., J Bingham, S., H Buch, M., G Conaghan, P., Gough, A., Green, M., Lawson, C., Pease, C., Markham, A.F., E R Ollier, W., Emery, P., Worthington, J. and Isaacs, J. Fc γ R11A-158V and rheumatoid arthritis: A confirmation study. *Rheumatology (Oxford).* 2003, **42**, pp.528-533.

2002

129. Ponchel, F., **Morgan, A.W.**, Bingham, S.J., Quinn, M., Buch, M., Verburg, R.J., Henwood, J., Douglas, S.H., Masurel, A., Conaghan, P., Gesinde, M., Taylor, J., Markham, A.F., Emery, P., van Laar, J.M. and Isaacs, J.D. Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. *Blood.* 2002, **100**, pp.4550-4556.
130. Donaldson, I.J., Shefta, J., Lawson, C.A., Bushnell, J.R., **Morgan, A.W.**, Isaacs, J.D., Carpenter, D., Shaw, M.-A., Rooth, I., Quinnell, R.J., Zumla, A.M., Ollier, W.E., Chintu, C.Z., Muyinda, G.P., Hill, A.V. and Boylston, A.W. Unique TCR β -subunit variable gene haplotypes in Africans. *Immunogenetics.* 2002, **53**, pp.884-893.

2001

131. McKibbin, M., Clark, B., Isaacs, J.D., Morrell, A.J., Griffiths, B., **Morgan, A.W.** and Gooi, H.C. Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting? *Eye.* 2001, **15**, pp.492-496.

132. McGonagle, D., Reade, S., Marzo-Ortega, H., Gibbon, W., O'Connor, P., **Morgan, A.**, Melsom, R., Morgan, E. and Emery, P. Human immunodeficiency virus associated spondyloarthritis: pathogenic insights based on imaging findings and response to highly active antiretroviral treatment. *Ann Rheum Dis.* 2001, **60**, pp.696-698.

2000

133. **Morgan, A.W.**, Griffiths, B., Ponchel, F., Montague, B.M.N., Ali, M., Gardner, P.P., Gooi, H.-C., Situnayake, R.D., Markham, A.F., Emery, P. and Isaacs, J.D. Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. *Arthritis Rheum.* 2000, **43**, pp.2328-2334.

1998

134. Hunter, A., **Morgan, A.W.** and Bird, H.A. A survey of Ehlers-Danlos syndrome: hearing, voice, speech and swallowing difficulties. Is there an underlying relationship? *Rheumatology.* 1998, **37**, pp.803-804.

1996

135. Grahame, R. and **Morgan, A.W.**, Dr. REPORT ON THE HYPERMOBILITY SPECIAL INTEREST GROUP, BRITISH SOCIETY FOR RHEUMATOLOGY MEETING IN GLASGOW, APRIL 1995. *Rheumatology.* 1996, **35**, pp.392-393.

1994

136. Troughton, P.R. and **Morgan, A.W.** Laboratory findings and pathology of psoriatic arthritis. *Baillière's Clinical Rheumatology.* 1994, **8**, pp.439-463.

1992

137. A. Bird, H. Reports from Special Interest Groups of the Annual General Meeting of the British Society for Rheumatology: JOINT HYPERMOBILITY. *Rheumatology.* 1992, **31**.

In Revision

1. Svasti-Salee, C., Mollan S. P., **Morgan, A.W.**, Quick V. Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. *In Revision BMJ Open Reports.*

Submitted Manuscripts

1. Teamzghi, F.M., **Morgan, A.W.**, West, R. M., Stewart, P.M., Pujades-Rodriguez, M. Oral glucocorticoids increase the risk of hypertension in people with chronic inflammatory diseases: findings from a population based cohort study in England. *Submitted CMAJ.*
2. Pujades-Rodriguez, M., **Morgan, A.W.**, Cubbon, R.M., Wu, J. Dose-dependent oral glucocorticoid cardiovascular risk in people with immune-mediated inflammatory diseases. *Submitted JAMA.*
3. Baxter, E.W., Graham, A.E., Re, N.A., Carr, I., Robinson, J.I., Mackie, S.L., **Morgan, A.W.** New optimized protocols for differentiation of THP-1 cells to classically-activated macrophages M(IFN γ + LPS) and alternatively-activated macrophages with distinct M(IL-4) and M(IL-10) phenotypes. *Submitted Front Immunol.*

4. Gilani, S., Plant, D., Hyrich, K., Wilson, A., Isaacs, J., Barton, A., BRAGGSS Consortium, Bluett, J. Pharmacogenetics of Anti-TNF Response in Rheumatoid Arthritis Utilising the Two-Component Disease Activity Score. *Submitted **Pharmacogenomics J.***
5. Erhayiem, B., McDiarmid, A.K., Swoboda, P.P., Kidambi, A., Gough, A., Dobson, L. E., Al Musa, T., Ripley, D., Garg, P., **Morgan, A.W.**, Plein, S., Greenwood, J.P., Mackie, S.L. Cardiovascular magnetic resonance reveals dilation of the thoracic aorta and hidden cardiovascular comorbidity in patients with giant cell arteritis: a cross-sectional pilot study. *Awaiting resubmission.*